The first Israeli SARS-CoV-2 vaccine was administered at Sheba Medical Center at Tel Hashomer in Ramat Gan on Sunday to the first volunteer in a clinical trial.

The vaccine, called “BriLife,” was developed by the Israel Institute of Biological Research (IIBR), which has prepared 25,000 doses ahead of the 80-person trial. Half of the volunteers will be given the vaccine (or a placebo) at Hadassah University Medical Center in Jerusalem and half at Sheba Medical Center.

In the first stage of the trials, the volunteers, ages 18 to 55, will be monitored for antibodies and side effects for three weeks after receiving an injection (vaccine or placebo). The second, wider stage is set to begin in December and will involve extensive safety tests on a group of 960 healthy volunteers in several medical centers across Israel. The third and final phase, which is scheduled for April or May, depending on the success of the first two stages, will test the vaccine’s efficacy with the participation of up to 30,000 volunteers.

The first dose was administered on Sunday at Sheba to Segev Harel, 26. The second was given to 34-year-old Anar Ottolenghi at Hadassah.

At a press conference at Sheba to mark the event, IIBR head professor Shmuel Shapira called the start of the clinical trials “a historic moment.”

Many people, said Shapira, had asked him if he was happy to have reached this point. The answer, he said, was no.

“I’m not happy. I’m proud,” he said, adding that the vaccine represented “an incredible scientific achievement.”

This achievement had been made in record time, he said, despite the fact that the IIBR had taken no shortcuts “of the kind enjoyed by the big corporations.”

“They all took shortcuts; we went the whole way,” he said.

Professor Dror Haratz, deputy director general of research and development at the hospital and the chairman of the Helsinki Committee that deals with research approval and human experimentation, assured reporters that “all possible measures” had been taken to ensure the volunteers’ safety.

“It should be remembered that this trial is based on a virus that has already been used for vaccines against Ebola, such that we know a great deal regarding … the dangers of this virus, and all things considered the risks are very small,” said Haratz. “And despite this, we are taking every possible precaution to protect the volunteers’ safety in this trial.”

“I can tell you that the State of Israel is considered to be a leader with respect to the regulation of clinical trials,” he added.

‘This is a very big thing’

Israeli Prime Minister Benjamin Netanyahu, who was present at the event, along with Defense Minister Benny Gantz and Health Minister Yuli Edelstein, said that a viable vaccine represented the true end of the pandemic in Israel.

“Therefore, this is a very important day, a day that gives us all—please forgive the expression—a shot in the arm,” he said. “We just met Segev, a 26-year-old Israeli man who volunteered to be the first on the frontline, and receive the experimental vaccine that was developed here by the talented scientists at the IIBR. We wish everyone success during this and the later stages [of the clinical trials]. With God’s help, we will have a vaccine made here in Israel. This is a very big thing.”

Netanyahu thanked Shapira, the IIBR and the Health Ministry for their work in developing the vaccine, but emphasized that Israel was also looking abroad for solutions.

In parallel with the development of an Israeli vaccine, said Netanyahu, Israel has been working with the big pharmaceutical companies, with the assistance of the Health Ministry, for access to their vaccines. He had also reached out personally to various world leaders, he said—including German Chancellor Angela Merkel, U.S. Vice President Mike Pence, Indian Prime Minister Narendra Modi, Russian President Vladimir Putin and Italian Prime Minister Giuseppe Conte—to ensure Israel “was at the front of the line, not the back.”

“What’s important is that, by whatever means, by means of local production that has been developed here or through the import of vaccines from abroad, we will get enough vaccine for all citizens of Israel. Then, finally, at long last, with God’s help, we will be free of the pandemic,” said Netanyahu.

“I do not think that this will happen immediately, but I do tell you that I already see the light at the end of the tunnel; I see vaccines in the State of Israel. Therefore, I have one request: that you pay heed to the regulations of the Health Ministry and corona Cabinet, which are designed for the benefit of the citizens of Israel. This is to safeguard your lives and your health. Above all, wear masks over the nose and mouth,” he said.

Support Jewish Journalism
with 2020 Vision

One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.

JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.

During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.

Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.